Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Apr. 23, 2015—Preemptive genotyping: It sounds like a surprise attack, and it is.
Oct. 24, 2013—With the aid of a two-year, $487,000 National Leadership Grant from the Institute of Museum and Library Services (IMLS), a Vanderbilt research team will develop a reusable model to promote better patient engagement with the health care team through delivery of consumer-friendly pharmacogenetic information.
Oct. 17, 2013—A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions.